Drug:
Reaction: DERMATITIS ATOPIC
20260101 - 20261231
No. 1 - 100
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1 | 26556124 |
US |
2 | |
Knee arthroplasty, Dermatitis atopic, |
||||
UPADACITINIB, |
||||
| 2 | 26556461 |
EU |
1 | 2 |
Jaundice, Muscle tightness, Metabolic disorder, Sleep disorder, Vaccination site induration, Dermatitis atopic, Infection, Upper respiratory tract infection, Vaccination site oedema, Mucous stools, Feeding disorder, Faeces discoloured, Crying, Urticaria, Abdominal pain, Oral candidiasis, Vaccination site erythema, Diarrhoea, Decreased appetite, Irritability, Weight gain poor, Altered state of consciousness, Diarrhoea haemorrhagic, Immune system disorder, Syncope, Poor feeding infant, Abdominal pain upper, Lethargy, Seizure, Dermatitis allergic, Nasopharyngitis, Somnolence, Erythema, Rash, Vaccination site pain, Nervousness, Vomiting, |
||||
| 3 | 26556950 |
US |
21 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 4 | 26557180 |
US |
15 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 5 | 26557252 |
US |
1 | |
Dermatitis atopic, Dry skin, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 6 | 26557320 |
US |
8 | 1 |
Illness, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 7 | 26557322 |
US |
67 | 2 |
Dermatitis atopic, Eye pruritus, Periorbital swelling, Eye pain, Fatigue, |
||||
DUPILUMAB, |
||||
| 8 | 26557402 |
US |
36 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 9 | 26557414 |
US |
28 | 2 |
Psoriasis, Dermatitis atopic, Product dose omission issue, Product use in unapproved indication, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 10 | 26557418 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 11 | 26557422 |
US |
18 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 12 | 26557424 |
US |
38 | 2 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 13 | 26557435 |
US |
38 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, RESMETIROM, |
||||
| 14 | 26557546 |
US |
45 | 2 |
Dermatitis atopic, Rash pruritic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 15 | 26557566 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, ALBUTEROL SULFATE, KETOCONAZOLE, KETOCONAZOLE FOAM, KETOCONAZOLE CREAM, 2%, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, |
||||
| 16 | 26557585 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 17 | 26557588 |
US |
62 | 1 |
Dermatitis atopic, Eczema, Skin exfoliation, Pruritus, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 18 | 26557977 |
US |
32 | 2 |
Dermatitis atopic, Pruritus, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, |
||||
| 19 | 26558041 |
US |
25 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, NITROGLYCERIN, |
||||
| 20 | 26558048 |
US |
13 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, MUPIROCIN, MUPIROCIN CALCIUM, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, |
||||
| 21 | 26558061 |
US |
1 | |
Pruritus, Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, WATER, ACONITUM NAP, ARSENICUM ALB, BORAX, CALC PHOS, GELSENIUM, LYCOPODIUM, PHOSPHORICUM AC, PICRICUM AC, PLUMB MET, SOLIDAGO, FLUTICASONE PROPIONATE, |
||||
| 22 | 26558146 |
US |
72 | 2 |
Dermatitis atopic, Pruritus, Dry skin, Skin exfoliation, Intentional product misuse, |
||||
DUPILUMAB, DUPILUMAB, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, PSYLLIUM HUSK, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, |
||||
| 23 | 26558158 |
US |
77 | 2 |
Upper respiratory tract infection, Dermatitis atopic, |
||||
DUPILUMAB, GABAPENTIN, VIBEGRON, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, SIMVASTATIN, |
||||
| 24 | 26558169 |
US |
1 | |
Dermatitis atopic, Condition aggravated, |
||||
DUPILUMAB, |
||||
| 25 | 26559077 |
US |
71 | |
Pneumonia, Asthma, Nasopharyngitis, Dermatitis atopic, |
||||
| 26 | 26560081 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 27 | 26560220 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 28 | 26560222 |
US |
39 | 1 |
Dry skin, Skin fissures, Dermatitis atopic, Intentional product misuse, |
||||
DUPILUMAB, KETOCONAZOLE, KETOCONAZOLE FOAM, KETOCONAZOLE CREAM, 2%, DIPHENHYDRAMINE HYDROCHLORIDE, ALBUTEROL SULFATE, |
||||
| 29 | 26560254 |
US |
42 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 30 | 26560278 |
US |
26 | 2 |
Dermatitis atopic, Rash, Discomfort, Sleep disorder, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 31 | 26560320 |
US |
56 | 1 |
Dermatitis atopic, Dry skin, Skin fissures, Skin exfoliation, |
||||
DUPILUMAB, |
||||
| 32 | 26560337 |
US |
15 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 33 | 26560339 |
US |
15 | 1 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 34 | 26560357 |
US |
18 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 35 | 26560370 |
US |
15 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 36 | 26560448 |
US |
33 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 37 | 26560477 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 38 | 26561492 |
US |
68 | |
Dermatitis atopic, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 39 | 26550020 |
US |
1 | |
Dermatitis atopic, Rash, Discomfort, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 40 | 26550034 |
US |
2 | |
Dermatitis atopic, Rash, Discomfort, Product dose omission in error, |
||||
DUPILUMAB, |
||||
| 41 | 26550049 |
US |
2 | |
Injection site pain, Injection site vesicles, Injection site rash, Dermatitis atopic, |
||||
DUPILUMAB, BIOTIN, LEMBOREXANT, FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE ORAL, FEXOFENADINE HCL, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE, LISDEXAMFETAMINE DIMESYLATE CAPSULES, MELATONIN, PIMECROLIMUS, PROPRANOLOL HYDROCHLORIDE, NORGESTIMATE AND ETHINYL ESTRADIOL, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, ERGOCALCIFEROL, |
||||
| 42 | 26550127 |
US |
11 | 1 |
Dermatitis atopic, Pruritus, Skin lesion, |
||||
DUPILUMAB, CEPHALEXIN, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, |
||||
| 43 | 26550154 |
US |
26 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 44 | 26550175 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 45 | 26550182 |
US |
62 | 1 |
Pruritus, Product dose omission issue, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 46 | 26550195 |
US |
2 | |
Dermatitis atopic, Incorrect dose administered, |
||||
DUPILUMAB, |
||||
| 47 | 26550207 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 48 | 26550251 |
US |
1 | |
Skin swelling, Product use in unapproved indication, Dermatitis atopic, |
||||
DUPILUMAB, ALBUTEROL SULFATE, AMLODIPINE BESYLATE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, CYANOCOBALAMIN, FENOFIBRATE, FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE NASAL, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, MECLIZINE HYDROCHLORIDE, MECLIZINE, MECLIZINE HYDROCLORIDE, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, METOPROLOL TARTRATE, METOROPROLOL TARTRATE, METOPROLOL, ONDANSETRON HYDROCHLORIDE, OXYBUTYNIN CHLORIDE, PRAMIPEXOLE, PANTOPRAZOLE SODIUM, SULFASALAZINE, TAMSULOSIN HYDROCHLORIDE, TIMOLOL MALEATE, TIMOLOL MALEATE OPHTHALMIC, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, DULAGLUTIDE, ERGOCALCIFEROL, |
||||
| 49 | 26550845 |
US |
69 | 1 |
Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, |
||||
| 50 | 26554218 |
IL |
49 | 2 |
Dermatitis atopic, Drug ineffective, |
||||
UPADACITINIB, |
||||
| 51 | 26549143 |
US |
77 | 2 |
Dermatitis atopic, Pain, Dyskinesia, |
||||
DUPILUMAB, |
||||
| 52 | 26549144 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 53 | 26549151 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 54 | 26549175 |
US |
25 | 2 |
Dermatitis atopic, Pruritus, Rash, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 55 | 26549179 |
US |
14 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 56 | 26549180 |
US |
5 | 2 |
Dermatitis atopic, Depressed mood, |
||||
DUPILUMAB, |
||||
| 57 | 26549184 |
US |
46 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 58 | 26549192 |
US |
1 | |
Dyspnoea, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 59 | 26549196 |
US |
24 | 1 |
Dermatitis atopic, Skin exfoliation, |
||||
DUPILUMAB, |
||||
| 60 | 26549198 |
US |
11 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 61 | 26549202 |
US |
62 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 62 | 26549219 |
US |
57 | 2 |
Dermatitis atopic, Urticaria, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 63 | 26549232 |
US |
7 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 64 | 26549241 |
US |
36 | 2 |
Dermatitis atopic, Maternal exposure during pregnancy, |
||||
DUPILUMAB, |
||||
| 65 | 26549245 |
US |
59 | 2 |
Dermatitis atopic, Intentional dose omission, |
||||
DUPILUMAB, |
||||
| 66 | 26549246 |
US |
28 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 67 | 26549248 |
US |
50 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 68 | 26549262 |
US |
63 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 69 | 26549267 |
US |
6 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 70 | 26549269 |
US |
45 | 1 |
Psoriasis, Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 71 | 26549272 |
US |
17 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 72 | 26549274 |
US |
57 | 1 |
Dermatitis atopic, Eczema, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 73 | 26549280 |
US |
40 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 74 | 26549282 |
US |
58 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 75 | 26549286 |
US |
7 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 76 | 26549287 |
US |
24 | 1 |
Dermatitis atopic, Umbilical hernia, |
||||
DUPILUMAB, |
||||
| 77 | 26549305 |
US |
47 | 1 |
Sleep disorder, Dermatitis atopic, Skin haemorrhage, Dry skin, Pruritus, |
||||
DUPILUMAB, |
||||
| 78 | 26549306 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 79 | 26549315 |
US |
20 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 80 | 26549338 |
US |
18 | 1 |
Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 81 | 26549348 |
US |
44 | 2 |
Dermatitis atopic, Asthma, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 82 | 26549352 |
US |
29 | 2 |
Injection site erythema, Injection site pain, Muscle tightness, Anxiety, Musculoskeletal stiffness, Erythema, Dermatitis atopic, Pruritus, Swelling, Dry skin, Wound, |
||||
DUPILUMAB, |
||||
| 83 | 26549354 |
US |
2 | |
Pruritus, Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 84 | 26549366 |
US |
8 | 2 |
Infection, Injection site pain, Dermatitis atopic, Dry skin, Pruritus, Swelling, Burning sensation, |
||||
DUPILUMAB, |
||||
| 85 | 26549370 |
US |
54 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 86 | 26549379 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 87 | 26549381 |
US |
7 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 88 | 26549399 |
US |
64 | 1 |
Dermatitis atopic, Pruritus, Skin burning sensation, Pain of skin, Injection site pain, |
||||
DUPILUMAB, |
||||
| 89 | 26549400 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 90 | 26549423 |
US |
61 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 91 | 26549431 |
US |
7 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 92 | 26549433 |
US |
62 | 1 |
Dermatitis atopic, Rash erythematous, |
||||
DUPILUMAB, |
||||
| 93 | 26549435 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 94 | 26549456 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 95 | 26549458 |
US |
29 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 96 | 26549494 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 97 | 26549500 |
US |
11 | 2 |
Dermatitis atopic, Off label use, |
||||
DUPILUMAB, |
||||
| 98 | 26549505 |
US |
25 | 2 |
Influenza, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 99 | 26549506 |
US |
30 | 2 |
Dermatitis atopic, Therapeutic response decreased, |
||||
DUPILUMAB, |
||||
| 100 | 26549509 |
US |
71 | 1 |
Dermatitis atopic, Pruritus, Therapeutic response shortened, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-04-28